205 results on '"Sanders GD"'
Search Results
52. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.
- Author
-
Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, and Ganiats TG
- Subjects
- Consensus, Delivery of Health Care trends, Guidelines as Topic, Humans, Medicine standards, Quality of Health Care, Cost-Benefit Analysis methods, Delivery of Health Care economics
- Abstract
Importance: Since publication of the report by the Panel on Cost-Effectiveness in Health and Medicine in 1996, researchers have advanced the methods of cost-effectiveness analysis, and policy makers have experimented with its application. The need to deliver health care efficiently and the importance of using analytic techniques to understand the clinical and economic consequences of strategies to improve health have increased in recent years., Objective: To review the state of the field and provide recommendations to improve the quality of cost-effectiveness analyses. The intended audiences include researchers, government policy makers, public health officials, health care administrators, payers, businesses, clinicians, patients, and consumers., Design: In 2012, the Second Panel on Cost-Effectiveness in Health and Medicine was formed and included 2 co-chairs, 13 members, and 3 additional members of a leadership group. These members were selected on the basis of their experience in the field to provide broad expertise in the design, conduct, and use of cost-effectiveness analyses. Over the next 3.5 years, the panel developed recommendations by consensus. These recommendations were then reviewed by invited external reviewers and through a public posting process., Findings: The concept of a "reference case" and a set of standard methodological practices that all cost-effectiveness analyses should follow to improve quality and comparability are recommended. All cost-effectiveness analyses should report 2 reference case analyses: one based on a health care sector perspective and another based on a societal perspective. The use of an "impact inventory," which is a structured table that contains consequences (both inside and outside the formal health care sector), intended to clarify the scope and boundaries of the 2 reference case analyses is also recommended. This special communication reviews these recommendations and others concerning the estimation of the consequences of interventions, the valuation of health outcomes, and the reporting of cost-effectiveness analyses., Conclusions and Relevance: The Second Panel reviewed the current status of the field of cost-effectiveness analysis and developed a new set of recommendations. Major changes include the recommendation to perform analyses from 2 reference case perspectives and to provide an impact inventory to clarify included consequences.
- Published
- 2016
- Full Text
- View/download PDF
53. An overview and discussion of the Patient-Centered Outcomes Research Institute's decision aid portfolio.
- Author
-
Gayer CC, Crowley MJ, Lawrence WF, Gierisch JM, Gaglio B, Williams JW Jr, Myers ER, Kendrick A, Slutsky J, and Sanders GD
- Subjects
- Academies and Institutes, Financial Management, Humans, Decision Support Techniques, Delivery of Health Care, Patient Outcome Assessment
- Abstract
Decision aids (DAs) help patients make informed healthcare decisions in a manner consistent with their values and preferences. Despite their promise, DAs developed with public research dollars are not being implemented and adopted in real-world patient care settings at a rate consistent with which they are being developed. To appraise the sum of the parts of the portfolio and create a strategic imperative surrounding future funding, the Patient-Centered Outcomes Research Institute (PCORI) tasked the Duke Evidence Synthesis Group with evaluating its DA portfolio. This paper describes PCORI's portfolio of DAs according to the Duke Evidence Synthesis Group's analysis in the context of PCORI's mission and the field of decision science. The results revealed a diversity within PCORI's portfolio of funded DA projects. Findings support the movement toward more rigorous DA development, assessment and maintenance. PCORI's funding priorities related to DAs are clarified and comparative questions of interest are posed.
- Published
- 2016
- Full Text
- View/download PDF
54. Response to Letter Regarding Article, "Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women".
- Author
-
Zeitler EP, Hellkamp AS, Schulte PJ, Fonarow GC, Hernandez AF, Peterson ED, Sanders GD, Yancy CW, and Al-Khatib SM
- Subjects
- Death, Sudden, Cardiac, Female, Humans, Defibrillators, Implantable, Primary Prevention
- Published
- 2016
- Full Text
- View/download PDF
55. Breast Cancer Screening: Benefit or Harm?--Reply.
- Author
-
Myers ER, Moorman P, and Sanders GD
- Subjects
- Female, Humans, Ultrasonography, Breast Neoplasms diagnostic imaging, Early Detection of Cancer, Mammography standards
- Published
- 2016
- Full Text
- View/download PDF
56. Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women.
- Author
-
Zeitler EP, Hellkamp AS, Schulte PJ, Fonarow GC, Hernandez AF, Peterson ED, Sanders GD, Yancy CW, and Al-Khatib SM
- Subjects
- Aged, Aged, 80 and over, Centers for Medicare and Medicaid Services, U.S., Chi-Square Distribution, Comparative Effectiveness Research, Electric Countershock adverse effects, Electric Countershock mortality, Female, Heart Failure diagnosis, Heart Failure mortality, Heart Failure physiopathology, Hospitalization, Humans, Kaplan-Meier Estimate, Logistic Models, Male, Markov Chains, Monte Carlo Method, Propensity Score, Proportional Hazards Models, Registries, Risk Assessment, Risk Factors, Sex Factors, Stroke Volume, Time Factors, Treatment Outcome, United States, Ventricular Function, Left, Defibrillators, Implantable, Electric Countershock instrumentation, Heart Failure therapy, Primary Prevention instrumentation
- Abstract
Background: Clinical trials of implantable cardioverter defibrillators (ICDs) for primary prevention enrolled a limited number of women. We sought to examine clinical practice data to compare survival rates among women with heart failure with or without a primary prevention ICD., Methods and Results: We linked data from 264 US hospitals included in the Get With The Guidelines for Heart Failure registry with data from the Centers for Medicare and Medicaid Services. From these sources, we propensity score matched 430 women with heart failure who received a primary prevention ICD to 430 women who did not; we further adjusted using a Cox proportional hazards model. Median follow-up was 3.4 and 3.0 years. For comparison, we matched 859 men receiving an ICD with 859 who did not; median follow-up was 3.9 versus 2.9 years. In the matched cohorts, an ICD was associated with similarly better survival in women (hazard ratio, 0.78; 95% confidence interval, 0.66-0.92; P=0.003) and men (hazard ratio, 0.76; 95% confidence interval, 0.67-0.87 P<0.001). There was no interaction between sex and presence of an ICD with respect to survival (P=0.79)., Conclusions: Among patients with heart failure with reduced left ventricular ejection fraction, a primary prevention ICD was associated with a significant survival advantage among women and among men. These findings support guideline-directed use of primary prevention ICDs in eligible patients., (© 2015 American Heart Association, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
57. Effects of Lumbosacral Manipulation on Isokinetic Strength of the Knee Extensors and Flexors in Healthy Subjects: A Randomized, Controlled, Single-Blind Crossover Trial.
- Author
-
Sanders GD, Nitz AJ, Abel MG, Symons TB, Shapiro R, Black WS, and Yates JW
- Abstract
Objective: The purpose of this study was to investigate the effect of manual manipulations targeting the lumbar spine and/or sacroiliac joint on concentric knee extension and flexion forces. Torque production was measured during isometric and isokinetic contractions., Methods: This was a randomized, controlled, single-blind crossover design with 21 asymptomatic, college-aged subjects who had never received spinal manipulation. During 2 separate sessions, subjects' peak torques were recorded while performing maximal voluntary contractions on an isokinetic dynamometer. Isometric knee extension and flexion were recorded at 60° of knee flexion, in addition to isokinetic measurements obtained at 60°/s and 180°/s. Baseline measurements were acquired before either treatment form of lumbosacral manipulation or sham manipulation, followed by identical peak torque measurements within 5 and 20 minutes posttreatment. Data were analyzed with a repeated measures analysis of variance., Results: A statistically significant difference did not occur between the effects of lumbosacral manipulation or the sham manipulation in the percentage changes of knee extension and flexion peak torques at 5 and 20 minutes posttreatment. Similar, nonsignificant results were observed in the overall percentage changes of isometric contractions (spinal manipulation 4.0 ± 9.5 vs sham 1.2 ± 6.3, P = .067), isokinetic contractions at 60°/s (spinal manipulation - 4.0 ± 14.2 vs sham - 0.3 ± 8.2, P = .34), and isokinetic contractions at 180°/s (spinal manipulation - 1.4 ± 13.9 vs sham - 5.5 ± 20.0, P = .18)., Conclusion: The results of the current study suggest that spinal manipulation does not yield an immediate strength-enhancing effect about the knee in healthy, college-aged subjects when measured with isokinetic dynamometry.
- Published
- 2015
- Full Text
- View/download PDF
58. Future Research Prioritization: Implantable Cardioverter-Defibrillator Therapy in Older Patients.
- Author
-
Al-Khatib SM, Gierisch JM, Crowley MJ, Coeytaux RR, Myers ER, Kendrick A, and Sanders GD
- Subjects
- Age Factors, Aged, Biomedical Research methods, Death, Sudden, Cardiac prevention & control, Evidence-Based Medicine methods, Humans, Patient Outcome Assessment, Patient Preference, Risk Factors, Biomedical Research trends, Defibrillators, Implantable adverse effects, Electric Countershock adverse effects
- Abstract
Background: Although the implantable cardioverter-defibrillator (ICD) is highly effective therapy for preventing sudden cardiac death, there is considerable uncertainty about its benefits and harms in older patients, especially in the presence of factors, other than old age, that increase the risk of death., Objective: To develop a prioritized research agenda for the Patient-Centered Outcomes Research Institute as informed by a diverse group of stakeholders on the use and outcomes of the ICD in older patients., Design: The existing literature was reviewed to identify evidence gaps, which were then refined by engaged stakeholders. Using a forced-ranking prioritization method, the stakeholders ranked evidence gaps by importance. For the highest-ranked evidence gaps, relevant recent studies were identified using PubMed, and relevant ongoing trials were identified using ClinicalTrials.gov., Participants: Eighteen stakeholders, including clinical experts and researchers in the prevention of sudden cardiac death and ICD therapy, representatives from federal and non-governmental funding agencies, representatives from relevant professional societies, health care decision-makers and policymakers, and representatives from related consumer and patient advocacy groups, Key Results: The top 12 evidence gaps prioritized by stakeholders were related to the safety and effectiveness of ICDs in older patient subgroups not well represented in clinical trials, predictors of SCD, the impact of the ICD on quality of life, the use of shared decision-making, disparities in ICD use, risk stratification strategies, patient preferences, and distribution of modes of death in older patients., Conclusions: In this paper, we identify evidence gaps of high priority for current and future investigations of ICD therapy. Addressing these gaps will likely resolve many of the uncertainties surrounding the use and outcomes of the ICD in older patients seen in clinical practice.
- Published
- 2015
- Full Text
- View/download PDF
59. Benefits and Harms of Breast Cancer Screening: A Systematic Review.
- Author
-
Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S, Davidson B, Mongtomery RC, Crowley MJ, McCrory DC, Kendrick A, and Sanders GD
- Subjects
- Adult, Biopsy, Breast Neoplasms mortality, False Positive Reactions, Female, Humans, Life Expectancy, Middle Aged, Physical Examination, Risk, Ultrasonography, Breast Neoplasms diagnostic imaging, Early Detection of Cancer, Mammography standards
- Abstract
Importance: Patients need to consider both benefits and harms of breast cancer screening., Objective: To systematically synthesize available evidence on the association of mammographic screening and clinical breast examination (CBE) at different ages and intervals with breast cancer mortality, overdiagnosis, false-positive biopsy findings, life expectancy, and quality-adjusted life expectancy., Evidence Review: We searched PubMed (to March 6, 2014), CINAHL (to September 10, 2013), and PsycINFO (to September 10, 2013) for systematic reviews, randomized clinical trials (RCTs) (with no limit to publication date), and observational and modeling studies published after January 1, 2000, as well as systematic reviews of all study designs. Included studies (7 reviews, 10 RCTs, 72 observational, 1 modeling) provided evidence on the association between screening with mammography, CBE, or both and prespecified critical outcomes among women at average risk of breast cancer (no known genetic susceptibility, family history, previous breast neoplasia, or chest irradiation). We used summary estimates from existing reviews, supplemented by qualitative synthesis of studies not included in those reviews., Findings: Across all ages of women at average risk, pooled estimates of association between mammography screening and mortality reduction after 13 years of follow-up were similar for 3 meta-analyses of clinical trials (UK Independent Panel: relative risk [RR], 0.80 [95% CI, 0.73-0.89]; Canadian Task Force: RR, 0.82 [95% CI, 0.74-0.94]; Cochrane: RR, 0.81 [95% CI, 0.74-0.87]); were greater in a meta-analysis of cohort studies (RR, 0.75 [95% CI, 0.69 to 0.81]); and were comparable in a modeling study (CISNET; median RR equivalent among 7 models, 0.85 [range, 0.77-0.93]). Uncertainty remains about the magnitude of associated mortality reduction in the entire US population, among women 40 to 49 years, and with annual screening compared with biennial screening. There is uncertainty about the magnitude of overdiagnosis associated with different screening strategies, attributable in part to lack of consensus on methods of estimation and the importance of ductal carcinoma in situ in overdiagnosis. For women with a first mammography screening at age 40 years, estimated 10-year cumulative risk of a false-positive biopsy result was higher (7.0% [95% CI, 6.1%-7.8%]) for annual compared with biennial (4.8% [95% CI, 4.4%-5.2%]) screening. Although 10-year probabilities of false-positive biopsy results were similar for women beginning screening at age 50 years, indirect estimates of lifetime probability of false-positive results were lower. Evidence for the relationship between screening and life expectancy and quality-adjusted life expectancy was low in quality. There was no direct evidence for any additional mortality benefit associated with the addition of CBE to mammography, but observational evidence from the United States and Canada suggested an increase in false-positive findings compared with mammography alone, with both studies finding an estimated 55 additional false-positive findings per extra breast cancer detected with the addition of CBE., Conclusions and Relevance: For women of all ages at average risk, screening was associated with a reduction in breast cancer mortality of approximately 20%, although there was uncertainty about quantitative estimates of outcomes for different breast cancer screening strategies in the United States. These findings and the related uncertainty should be considered when making recommendations based on judgments about the balance of benefits and harms of breast cancer screening.
- Published
- 2015
- Full Text
- View/download PDF
60. Complications from prophylactic replacement of cardiac implantable electronic device generators in response to United States Food and Drug Administration recall: A systematic review and meta-analysis.
- Author
-
Zeitler EP, Patel D, Hasselblad V, Sanders GD, and Al-Khatib SM
- Subjects
- Humans, Risk Assessment, United States, United States Food and Drug Administration, Defibrillators, Implantable adverse effects, Defibrillators, Implantable statistics & numerical data, Device Removal adverse effects, Device Removal methods, Device Removal statistics & numerical data, Equipment Failure statistics & numerical data, Medical Device Recalls, Postoperative Complications classification, Postoperative Complications epidemiology, Reoperation adverse effects, Reoperation methods, Reoperation statistics & numerical data
- Abstract
Background: The number of cardiac implantable electronic device (CIED) recalls and advisories has increased over the past 3 decades, yet no consensus exists on how to best manage patients with these CIEDs, partially because rates of complications from prophylactic replacement are unknown., Objective: The purpose of this study was to establish rates of complications when recalled CIED generators are replaced prophylactically., Methods: We searched MEDLINE and the Cochrane Controlled Trials Register for reports of prophylactic replacement of recalled CIED generators. Studies with <20 subjects were excluded. We then conducted a meta-analysis of qualifying studies to determine the rates of combined major complications, mortality, and reoperation., Results: We identified 7 citations that met our inclusion criteria and reported ≥1 end-points of interest. Four were single center, and 3 were multicenter. Six studies collected data retrospectively (n = 1213) and 1 prospectively (n = 222). Using a random effects model to combine data from all included studies, the rate of major complications was 2.5% (95% confidence interval [CI] 1.0%-4.5%). Combining data from 6 studies reporting mortality and reoperation, the rates were 0.5% (95% CI 0.1%-0.9%) and 2.5% (95% CI 0.8%-4.5%), respectively., Conclusion: Prophylactic replacement of recalled CIED generators is associated with a low mortality rate but nontrivial rates of other major complications similar to those reported when CIED generators are replaced for other reasons. Thus, when considering replacing a recalled CIED generator, known risks of elective generator replacement likely apply and can be weighed against risks associated with device failure., (Copyright © 2015 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
61. Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study.
- Author
-
Pun PH, Hellkamp AS, Sanders GD, Middleton JP, Hammill SC, Al-Khalidi HR, Curtis LH, Fonarow GC, and Al-Khatib SM
- Subjects
- Aged, Aged, 80 and over, Death, Sudden, Cardiac epidemiology, Female, Heart Failure mortality, Humans, Incidence, Kidney Failure, Chronic mortality, Male, Middle Aged, Primary Prevention, Propensity Score, Proportional Hazards Models, Registries, Retrospective Studies, Death, Sudden, Cardiac prevention & control, Defibrillators, Implantable, Heart Failure complications, Kidney Failure, Chronic complications, Renal Dialysis methods
- Abstract
Background: Sudden cardiac death is the leading cause of death among end-stage kidney disease patients (ESKD) on dialysis, but the benefit of primary prevention implantable cardioverter defibrillators (ICDs) in this population is uncertain. We conducted this investigation to compare the mortality of dialysis patients receiving a primary prevention ICD with matched controls., Methods: We used data from the National Cardiovascular Data Registry's ICD Registry to select dialysis patients who received a primary prevention ICD, and the Get with the Guidelines-Heart Failure Registry to select a comparator cohort. We matched ICD recipients and no-ICD patients using propensity score techniques to reduce confounding, and overall survival was compared between groups., Results: We identified 108 dialysis patients receiving primary prevention ICDs and 195 comparable dialysis patients without ICDs. One year (3-year) mortality was 42.2% (68.8%) in the ICD registry cohort compared with 38.1% (75.7%) in the control cohort. There was no significant survival advantage associated with ICD [hazard ratio (HR) 0.87, 95% confidence interval (CI) 0.66-1.13, log-rank P = 0.29]. After propensity matching, our analysis included 86 ICD patients and 86 matched controls. Comparing the propensity-matched cohorts, 1 year (3 years) mortality was 43.4% (74.0%) in the ICD cohort and 39.7% (76.6%) in the control cohort; there was no significant difference in mortality outcome between groups (HR = 0.94, 95% CI: 0.67-1.31, log-rank P = 0.71)., Conclusions: We did not observe a significant association between primary prevention ICDs and reduced mortality among ESKD patients receiving dialysis. Consideration of the potential risks and benefits of ICD implantation in these patients should be undertaken while awaiting the results of definitive clinical trials., (© The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
62. Primary prevention implantable cardioverter-defibrillators and survival in older women.
- Author
-
Zeitler EP, Hellkamp AS, Fonarow GC, Hammill SC, Curtis LH, Hernandez AF, Al-Khalidi HR, Curtis JP, Heidenreich PA, Anstrom KJ, Peterson ED, Mark DB, Hammill BG, Sanders GD, and Al-Khatib SM
- Subjects
- Adrenergic beta-Antagonists therapeutic use, Aged, Aged, 80 and over, Angiotensin Receptor Antagonists therapeutic use, Female, Humans, Male, Primary Prevention, Propensity Score, Registries, United States epidemiology, Defibrillators, Implantable, Heart Failure mortality, Heart Failure therapy, Ventricular Dysfunction, Left mortality, Ventricular Dysfunction, Left therapy
- Abstract
Objectives: The purpose of this study was to assess the benefit of primary prevention implantable cardioverter defibrillators (ICDs) in women., Background: Clinical trials of primary prevention ICDs enrolled a limited number of women., Methods: Using a propensity score method, we matched 490 women ≥65 years of age who received an ICD during a hospitalization for heart failure in the National Cardiovascular Data Registry ICD Registry from January 1, 2006, through December 31, 2007, to 490 ICD-eligible women without an ICD hospitalized for heart failure in the Get With The Guidelines for Heart Failure database from January 1, 2006, through December 31, 2009. The primary endpoint was all-cause mortality obtained from the Medicare Claims Database. An identical analysis was conducted in men., Results: Median follow-up for patients with an ICD was 4.6 years versus 3.2 years for patients with no ICD. Compared with women with no ICD, those with an ICD were younger and less frequently white. In the matched cohorts, the survival of women with an ICD was significantly longer than that of women without an ICD (adjusted hazard ratio: 0.79, 95% confidence interval: 0.66 to 0.95; p = 0.013). Similarly, men with an ICD had longer survival than men without an ICD (adjusted hazard ratio: 0.73, 95% confidence interval: 0.65 to 0.83; p < 0.0001). There was no interaction between sex and the presence of an ICD with respect to survival (p = 0.44)., Conclusions: Among older women with left ventricular dysfunction, a primary prevention ICD was associated with a significant survival benefit that was nearly identical to that seen in men. These findings support the use of primary prevention ICDs in eligible patients regardless of sex., (Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
63. Incidence and predictors of appropriate therapies delivered by the implantable cardioverter defibrillator in patients with ischemic cardiomyopathy: a systematic review.
- Author
-
Gracieux J, Sanders GD, Pokorney SD, Lopes RD, Thomas K, and Al-Khatib SM
- Subjects
- Cardiomyopathies diagnosis, Clinical Trials as Topic methods, Defibrillators, Implantable trends, Female, Humans, Incidence, Male, Myocardial Ischemia diagnosis, Predictive Value of Tests, Cardiomyopathies epidemiology, Cardiomyopathies therapy, Defibrillators, Implantable statistics & numerical data, Myocardial Ischemia epidemiology, Myocardial Ischemia therapy
- Abstract
Background: Although the implantable cardioverter defibrillator (ICD) improves the survival of patients at increased risk of sudden cardiac death due to systolic heart failure, ICD shocks have been associated with both worse survival and quality of life. We performed a systematic review of primary prevention ICD studies to evaluate the incidence and clinical predictors of appropriate ICD shocks or anti-tachycardia pacing (ATP) in patients with ischemic cardiomyopathy., Methods: We performed a literature search in MEDLINE. Eligible studies had to be full text, written in the English language, performed in adults aged ≥ 19, and published from 1999 through April 2014., Results: Of 289 identified studies, 9 met all our inclusion criteria. The mean length of follow up ranged from 17 to 45.5 months. The incidence of appropriate ICD therapy varied from 17% to 31%. Among those studies, only 4 included data on the clinical characteristics of appropriate ICD therapy recipients. Characteristics associated with appropriate ICD therapy included male sex, advanced New York Heart Association class, non-sustained ventricular tachycardia, and lower serum creatinine. Patients who received appropriate therapy were also less likely to be on a beta-blocker. Left ventricular ejection fraction was not significantly different between patients who received appropriate ICD therapy and those who did not., Conclusion: The incidence of appropriate ICD therapy is not trivial in patients with ischemic cardiomyopathy and a primary prevention ICD. Predictors of appropriate ICD therapy have not been adequately assessed in large patient populations. As such, large prospective studies of predictors of appropriate ICD therapies are needed., (Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
64. Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials.
- Author
-
Steinberg BA, Al-Khatib SM, Edwards R, Han J, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Inoue LY, and Sanders GD
- Subjects
- Death, Sudden, Cardiac prevention & control, Female, Heart Failure complications, Humans, Male, Middle Aged, Multicenter Studies as Topic, Primary Prevention, Prospective Studies, Randomized Controlled Trials as Topic, Stroke Volume, Treatment Outcome, Defibrillators, Implantable, Heart Failure therapy
- Abstract
Objectives: The aim of this study was to determine if the benefit of implantable cardioverter-defibrillators (ICDs) is modulated by medical comorbidity., Background: Primary prevention ICDs improve survival in patients at risk for sudden cardiac death. Their benefit in patients with significant comorbid illness has not been demonstrated., Methods: Original, patient-level datasets from MADIT I (Multicenter Automatic Defibrillator Implantation Trial I), MADIT II, DEFINITE (Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation), and SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) were combined. Patients in the combined population (N = 3,348) were assessed with respect to the following comorbidities: smoking, pulmonary disease, diabetes, peripheral vascular disease, atrial fibrillation, ischemic heart disease, and chronic kidney disease. The primary outcome was overall mortality, using the hazard ratio (HR) of time to death for patients receiving an ICD versus no ICD by extent of medical comorbidity, and adjusted for age, sex, race, left ventricular ejection fraction, use of antiarrhythmic drugs, beta-blockers, and angiotensin-converting enzyme inhibitors., Results: Overall, 25% of patients (n = 830) had <2 comorbid conditions versus 75% (n = 2,518) with significant comorbidity (≥2). The unadjusted hazard of death for patients with an ICD versus no ICD was significantly lower, but this effect was less for patients with ≥2 comorbidities (unadjusted HR: 0.71; 95% confidence interval: 0.61 to 0.84) compared with those with <2 comorbidities (unadjusted HR: 0.59; 95% confidence interval: 0.40 to 0.87). After adjustment, the benefit of an ICD decreased with increasing number of comorbidities (p = 0.004)., Conclusions: Patients with extensive comorbid medical illnesses may experience less benefit from primary prevention ICDs than those with less comorbidity; implantation should be carefully considered in sick patients. Further study of ICDs in medically complex patients is warranted., (Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
65. Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease.
- Author
-
Hess PL, Hellkamp AS, Peterson ED, Sanders GD, Al-Khalidi HR, Curtis LH, Hammill BG, Pun PH, Curtis JP, Anstrom KJ, Hammill SC, and Al-Khatib SM
- Subjects
- Aged, Cause of Death, Chi-Square Distribution, Comorbidity, Electric Countershock adverse effects, Female, Glomerular Filtration Rate, Heart Failure diagnosis, Humans, Kaplan-Meier Estimate, Kidney physiopathology, Linear Models, Male, Middle Aged, Multivariate Analysis, Patient Selection, Proportional Hazards Models, Prosthesis Design, Registries, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic physiopathology, Risk Assessment, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, United States epidemiology, Death, Sudden, Cardiac prevention & control, Defibrillators, Implantable, Electric Countershock instrumentation, Electric Countershock mortality, Heart Failure mortality, Heart Failure therapy, Primary Prevention instrumentation, Renal Insufficiency, Chronic mortality
- Abstract
Background: Guidelines recommend that implantable cardioverter-defibrillator (ICD) candidates have an estimated longevity of ≥1 year. Longevity can be affected by chronic kidney disease (CKD)., Methods and Results: Using the National Cardiovascular Data Registry ICD registry linked with the Social Security Death Master File, we assessed the rate of death after primary prevention ICD placement between January 1, 2006, and December 31, 2007, according to CKD stage. Using Cox models, we identified factors associated with death among patients with CKD. Compared with patients without CKD (n=26,056), those with CKD (n=21,226) were older, less commonly men, more often white, and more frequently had comorbid illness. Compared with patients without CKD, patients with a glomerular filtration rate 30 to 60, glomerular filtration rate <30, and end-stage renal disease on dialysis had a higher risk of death after ICD placement (hazard ratio, 2.08; 95% confidence interval, 1.99-2.18; P<0.0001; hazard ratio, 4.20; 95% confidence interval, 3.92-4.50; P<0.0001; and hazard ratio, 4.80; 95% confidence interval, 4.46-5.17; P<0.0001, respectively). Corresponding 1-year death rates were 4.4%, 9.1%, 20.2%, and 22.4%. Among patients with CKD, factors associated with increased risk of death included CKD severity, age >65 years, heart failure symptoms, diabetes mellitus, lung disease, serum sodium <140 mEq/L, atrial fibrillation or flutter, and a lower ejection fraction., Conclusions: The risk of death after primary prevention ICD placement is proportional to CKD severity. Among patients with CKD, several factors are prognostically significant and could inform clinical decision making on primary prevention ICD candidacy., (© 2014 American Heart Association, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
66. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials.
- Author
-
Pun PH, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Hess PL, Inoue LY, and Sanders GD
- Subjects
- Aged, Female, Glomerular Filtration Rate physiology, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Patient Readmission statistics & numerical data, Randomized Controlled Trials as Topic, Renal Insufficiency, Chronic physiopathology, Risk Factors, Death, Sudden, Cardiac prevention & control, Defibrillators, Implantable, Primary Prevention, Renal Insufficiency, Chronic complications
- Abstract
Background: The benefit of a primary prevention implantable cardioverter-defibrillator (ICD) among patients with chronic kidney disease is uncertain., Study Design: Meta-analysis of patient-level data from randomized controlled trials., Setting & Population: Patients with symptomatic heart failure and left ventricular ejection fraction<35%., Selection Criteria for Studies: From 7 available randomized controlled studies with patient-level data, we selected studies with available data for important covariates. Studies without patient-level data for baseline estimated glomerular filtration rate (eGFR) were excluded., Intervention: Primary prevention ICD versus usual care effect modification by eGFR., Outcomes: Mortality, rehospitalizations, and effect modification by eGFR., Results: We included data from the Multicenter Automatic Defibrillator Implantation Trial I (MADIT-I), MADIT-II, and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 2,867 patients were included; 36.3% had eGFR<60 mL/min/1.73m2. Kaplan-Meier estimate of the probability of death during follow-up was 43.3% for 1,334 patients receiving usual care and 35.8% for 1,533 ICD recipients. After adjustment for baseline differences, there was evidence that the survival benefit of ICDs in comparison to usual care depends on eGFR (posterior probability for null interaction P<0.001). The ICD was associated with survival benefit for patients with eGFR≥60 mL/min/1.73 m2 (adjusted HR, 0.49; 95% posterior credible interval, 0.24-0.95), but not for patients with eGFR<60 mL/min/1.73 m2 (adjusted HR, 0.80; 95% posterior credible interval, 0.40-1.53). eGFR did not modify the association between the ICD and rehospitalizations., Limitations: Few patients with eGFR<30 mL/min/1.73 m2 were available. Differences in trial-to-trial measurement techniques may lead to residual confounding., Conclusions: Reductions in baseline eGFR decrease the survival benefit associated with the ICD. These findings should be confirmed by additional studies specifically targeting patients with varying eGFRs., (Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
67. Use Of Rate And Rhythm Control Drugs In Patients Younger Than 65 Years With Atrial Fibrillation.
- Author
-
LaPointe NM, Lokhnygina Y, Rimmler J, Sanders GD, Peterson ED, and Al-Khatib SM
- Abstract
Little is known about the use of pharmacologic rhythm or rate control in younger atrial fibrillation (AF) patients in clinical practice. Using commercial health data from 2006 through 2010, patients aged <65 years with an initial AF encounter were categorized as receiving pharmacologic rhythm- or rate-control treatment. Factors associated with each treatment were determined. Cox models with inverse propensity-weighted estimators were used to compare times to AF, heart failure, cardiovascular, non-cardiovascular, and any-cause hospitalizations. Of 79,232 patients meeting the study criteria, 12,408 (16%) received a rhythm-control drug and 66,824 (84%) received only rate-controlling drugs. Only 2% and 0.1%, respectively, received electrical cardioversion and AF ablation during the initial AF encounter. Patients who were men (OR 1.10, 95% CI 1.06-1.15), had index encounters in later years (2010 versus 2006: OR 1.34, 95% CI 1.23-1.45), were in the southern United States, and had other cardiac comorbidities were more likely to receive a rhythm-control drug. There was a greater risk of AF (HR 1.40, 95% CI 1.31-1.50), cardiovascular (HR 1.26, 95% CI 1.20-1.33), and all-cause (HR 1.11, 95% CI 1.07-1.16) hospitalizations in the rhythm-control group, but there was no difference between groups in heart failure (HR 1.01, 95% CI 0.88-1.17) or non-cardiovascular (HR 1.04, 95% CI 0.99-1.09) hospitalizations. Among younger AF patients receiving initial pharmacologic treatment, antiarrhythmic drugs were used less frequently than only rate-controlling drugs, and were associated with a higher risk of subsequent hospitalization.
- Published
- 2014
- Full Text
- View/download PDF
68. Prioritization of patient-centered comparative effectiveness research for osteoarthritis.
- Author
-
Gierisch JM, Myers ER, Schmit KM, McCrory DC, Coeytaux RR, Crowley MJ, Chatterjee R, Kendrick AS, and Sanders GD
- Subjects
- Health Priorities, Humans, Comparative Effectiveness Research, Osteoarthritis therapy, Patient-Centered Care
- Abstract
Osteoarthritis is a leading cause of disability in the United States. This article describes a prioritized research agenda about osteoarthritis management developed for the Patient-Centered Outcomes Research Institute. Evidence gaps were identified by reviewing existing literature and engaging diverse stakeholders to expand and refine gaps. Stakeholders ranked evidence gaps by importance from their perspectives.Prioritized evidence gaps included the need to determine or evaluate key patient-centered outcomes; optimal duration, intensity, and frequency of nonsurgical interventions; whether the comparative effectiveness of nonsurgical interventions varies by socioeconomic factors; when and how to transition from nonsurgical to surgical interventions; effective ways to engage patients in self-management and promote long-term behavior change; standardized screening tools that improve early diagnosis; biomechanical strategies that improve symptoms; mechanisms for promoting and delivering coordinated, longitudinal care; and comparative effectiveness of nonsurgical therapies. Searches of PubMed and ClinicalTrials.gov showed many recent and ongoing studies addressing comparative effectiveness of nonsurgical interventions; relatively few of these evaluated treatments across categories (for example, drug therapy vs. weight management) or combined categories of treatment. Few studies addressed other high-priority evidence gaps.
- Published
- 2014
- Full Text
- View/download PDF
69. Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%.
- Author
-
Al-Khatib SM, Hellkamp AS, Fonarow GC, Mark DB, Curtis LH, Hernandez AF, Anstrom KJ, Peterson ED, Sanders GD, Al-Khalidi HR, Hammill BG, Heidenreich PA, and Hammill SC
- Subjects
- Aged, Aged, 80 and over, Cohort Studies, Female, Heart Failure mortality, Humans, Male, Medicare statistics & numerical data, Propensity Score, Registries, Retrospective Studies, Risk, Survival Analysis, United States, Ventricular Function, Left, Defibrillators, Implantable, Heart Failure therapy, Ventricular Dysfunction, Left
- Abstract
Importance: Clinical trials of prophylactic implantable cardioverter-defibrillators (ICDs) have included a minority of patients with a left ventricular ejection fraction (LVEF) between 30% and 35%. Because a large number of ICDs in the United States are implanted in such patients, it is important to study survival associated with this therapy., Objective: To characterize patients with LVEF between 30% and 35% and compare the survival of those with and without ICDs., Design, Setting, and Participants: Retrospective cohort study of Medicare beneficiaries in the National Cardiovascular Data Registry ICD registry (January 1, 2006, through December 31, 2007) with an LVEF between 30% and 35% who received an ICD during a heart failure hospitalization and similar patients in the Get With The Guidelines-Heart Failure (GWTG-HF) database (January 1, 2005, through December 31, 2009) with no ICD. The analysis was repeated in patients with an LVEF less than 30%. There were 3120 patients with an LVEF between 30% and 35% (816 in matched cohorts) and 4578 with an LVEF less than 30% (2176 in matched cohorts). Propensity score matching and Cox models were applied., Main Outcomes and Measures: The primary outcome was all-cause mortality; data were obtained from Medicare claims through December 31, 2011., Results: There were no significant differences in the baseline characteristics of the matched groups (n = 408 for both groups). Among patients with an LVEF between 30% and 35%, there were 248 deaths in the ICD Registry group, within a median follow-up of 4.4 years (interquartile range, 2.7-4.9) and 249 deaths in the GWTG HF group, within a median follow-up of 2.9 years (interquartile range, 2.1-4.4). The risk of all-cause mortality in patients with an LVEF between 30% and 35% and an ICD was significantly lower than that in matched patients without an ICD (3-year mortality rates: 51.4% vs 55.0%; hazard ratio, 0.83 [95% CI, 0.69-0.99]; P = .04). Presence of an ICD also was associated with better survival in patients with an LVEF less than 30% (3-year mortality rates: 45.0% vs 57.6%; 634 and 660 total deaths; hazard ratio, 0.72 [95% CI, 0.65-0.81]; P < .001) (P = .20 for interaction)., Conclusions and Relevance: Among Medicare beneficiaries hospitalized for heart failure and with an LVEF between 30% and 35% and less than 30%, survival at 3 years was better in patients who received a prophylactic ICD than in comparable patients with no ICD. These findings support guideline recommendations to implant prophylactic ICDs in eligible patients with an LVEF of 35% or less.
- Published
- 2014
- Full Text
- View/download PDF
70. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review.
- Author
-
Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, Lopes RD, Povsic TJ, Raju SS, Shah B, Kosinski AS, McBroom AJ, and Sanders GD
- Subjects
- Atrial Fibrillation drug therapy, Heart Rate, Humans, Anti-Arrhythmia Agents therapeutic use, Atrial Fibrillation therapy, Catheter Ablation, Electric Countershock
- Abstract
Background: The comparative effectiveness of treatments for atrial fibrillation (AF) is uncertain., Purpose: To evaluate the comparative effectiveness of rate- and rhythm-control therapies., Data Sources: English-language studies in PubMed, EMBASE, and the Cochrane Database of Systematic Reviews between January 2000 and November 2013., Study Selection: Two reviewers independently screened citations to identify comparative studies that assessed rate- or rhythm-control therapies in patients with AF., Data Extraction: Reviewers extracted data on study design, participant characteristics, interventions, outcomes, applicability, and quality., Data Synthesis: 200 articles (162 studies) involving 28,836 patients were included. When pharmacologic rate- and rhythm-control strategies were compared, strength of evidence (SOE) was moderate supporting comparable efficacy with regard to all-cause mortality (odds ratio [OR], 1.34 [95% CI, 0.89 to 2.02]), cardiac mortality (OR, 0.96 [CI, 0.77 to 1.20]), and stroke (OR, 0.99 [CI, 0.76 to 1.30]) in older patients with mild AF symptoms. Few studies compared rate-control therapies and included outcomes of interest, which limited conclusions. For the effect of rhythm-control therapies in reducing AF recurrence, SOE was high favoring pulmonary vein isolation versus antiarrhythmic medications (OR, 5.87 [CI, 3.18 to 10.85]) and the surgical maze procedure (including pulmonary vein isolation) done during other cardiac surgery versus other cardiac surgery alone (OR, 7.94 [CI, 3.63 to 17.36])., Limitation: Studies were heterogeneous in interventions, populations, settings, and outcomes., Conclusion: Pharmacologic rate- and rhythm-control strategies have comparable efficacy across outcomes in primarily older patients with mild AF symptoms. Pulmonary vein isolation is better than antiarrhythmic medications at reducing recurrences of AF in younger patients with paroxysmal AF and mild structural heart disease. Future research should address uncertainties related to subgroups of interest and the effect of different therapies on long-term clinical outcomes., Primary Funding Source: Agency for Healthcare Research and Quality.
- Published
- 2014
- Full Text
- View/download PDF
71. Prioritization of research addressing antipsychotics for adolescents and young adults with bipolar disorder.
- Author
-
Crowley MJ, McCrory DC, Chatterjee R, Gierisch JM, Myers ER, Schmit KM, Coeytaux RR, Correll CU, Kendrick AS, and Sanders GD
- Subjects
- Adolescent, Adult, Comparative Effectiveness Research, Evidence-Based Medicine, Forecasting, Humans, Research Design, Young Adult, Antipsychotic Agents therapeutic use, Bipolar Disorder drug therapy, Patient Outcome Assessment, Research
- Abstract
Despite a paucity of high-quality evidence about benefits and harms, antipsychotic medication use among adolescents and young adults with bipolar disorder is increasing. The Patient-Centered Outcomes Research Institute tasked the Duke Evidence Synthesis Group with creating a prioritized agenda for research in this area that would incorporate the perspectives of relevant stakeholders. We identified a list of potential evidence gaps by reviewing existing literature and engaged a diverse group of 9 stakeholders to expand and refine this list. Using a forced-ranking prioritization method, stakeholders prioritized 10 of 23 potential evidence gaps as the most pressing for future research. These evidence gaps relate to 3 areas: the comparative effectiveness of intervention strategies, the effect of antipsychotics on patient-centered outcomes, and the influence of various patient characteristics on antipsychotic effectiveness. In addition to presenting these findings, we suggest appropriate study designs for addressing the stakeholder-prioritized research questions.
- Published
- 2014
- Full Text
- View/download PDF
72. Prioritization of research addressing management strategies for ductal carcinoma in situ.
- Author
-
Gierisch JM, Myers ER, Schmit KM, Crowley MJ, McCrory DC, Chatterjee R, Coeytaux RR, Kendrick A, and Sanders GD
- Subjects
- Adult, Evidence-Based Medicine, Female, Forecasting, Humans, Research Design, Breast Neoplasms therapy, Carcinoma, Intraductal, Noninfiltrating therapy, Patient Outcome Assessment, Research trends
- Abstract
Ductal carcinoma in situ is a common finding in women having mammography screening, and there is considerable uncertainty about the balance of harms and benefits of different management options. This article outlines the process for developing a prioritized research agenda for the Patient-Centered Outcomes Research Institute as informed by a diverse group of stakeholders on the management of ductal carcinoma in situ. Evidence gaps were identified by reviewing existing literature and engaging diverse stakeholders to refine these gaps. Stakeholders ranked evidence gaps by importance from their perspectives using a forced-ranking prioritization method. PubMed was searched for relevant recent studies, and ClinicalTrials.gov was searched for relevant ongoing trials for the 10 highest-ranked evidence gaps. Strengths and limitations of different study designs were assessed to address gaps. Stakeholders prioritized evidence gaps related to incorporation of patient-centered outcomes into future research, development of better methods to predict risk for invasive cancer, evaluation of a strategy of active surveillance, and testing of decision-making tools. The degree to which prioritized evidence gaps may have already been addressed is uncertain because a comprehensive systematic review has not been done.
- Published
- 2014
- Full Text
- View/download PDF
73. Ultrafast generation of fundamental and multiple-order phonon excitations in highly enriched (6,5) single-wall carbon nanotubes.
- Author
-
Lim YS, Nugraha AR, Cho SJ, Noh MY, Yoon EJ, Liu H, Kim JH, Telg H, Hároz EH, Sanders GD, Baik SH, Kataura H, Doorn SK, Stanton CJ, Saito R, Kono J, and Joo T
- Abstract
Using a macroscopic ensemble of highly enriched (6,5) single-wall carbon nanotubes, combined with high signal-to-noise ratio and time-dependent differential transmission spectroscopy, we have generated vibrational modes in an ultrawide spectral range (10-3000 cm(-1)). A total of 14 modes were clearly resolved and identified, including fundamental modes of A, E1, and E2 symmetries and their combinational modes involving two and three phonons. Through comparison with continuous wave Raman spectra as well as calculations based on an extended tight-binding model, we were able to identify all the observed peaks and determine the frequencies of the individual and combined modes. We provide a full summary of phonon frequencies for (6,5) nanotubes that can serve as a basic reference with which to refine our understanding of nanotube phonon spectra as well as a testbed for new theoretical models.
- Published
- 2014
- Full Text
- View/download PDF
74. Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator?
- Author
-
Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton AE, Cappato R, Dorian P, Hallstrom A, Kadish AH, Kudenchuk PJ, Lee KL, Mark DB, Moss AJ, Steinman R, Inoue LY, and Sanders GD
- Subjects
- Aged, Female, Heart Failure, Systolic mortality, Humans, Male, Middle Aged, Primary Prevention, Randomized Controlled Trials as Topic, Treatment Outcome, Death, Sudden, Cardiac prevention & control, Defibrillators, Implantable, Heart Failure, Systolic physiopathology, Heart Failure, Systolic therapy, Stroke Volume physiology
- Published
- 2014
- Full Text
- View/download PDF
75. Towards an absolute chronology for the Aegean iron age: new radiocarbon dates from Lefkandi, Kalapodi and Corinth.
- Author
-
Toffolo MB, Fantalkin A, Lemos IS, Felsch RC, Niemeier WD, Sanders GD, Finkelstein I, and Boaretto E
- Subjects
- Archaeology, Greece, Mediterranean Region, Time Factors, Artifacts, Radiometric Dating
- Abstract
The relative chronology of the Aegean Iron Age is robust. It is based on minute stylistic changes in the Submycenaean, Protogeometric and Geometric styles and their sub-phases. Yet, the absolute chronology of the time-span between the final stages of Late Helladic IIIC in the late second millennium BCE and the archaic colonization of Italy and Sicily toward the end of the 8(th) century BCE lacks archaeological contexts that can be directly related to events carrying absolute dates mentioned in Egyptian/Near Eastern historical sources, or to well-dated Egyptian/Near Eastern rulers. The small number of radiocarbon dates available for this time span is not sufficient to establish an absolute chronological sequence. Here we present a new set of short-lived radiocarbon dates from the sites of Lefkandi, Kalapodi and Corinth in Greece. We focus on the crucial transition from the Submycenaean to the Protogeometric periods. This transition is placed in the late 11(th) century BCE according to the Conventional Aegean Chronology and in the late 12(th) century BCE according to the High Aegean Chronology. Our results place it in the second half of the 11(th) century BCE.
- Published
- 2013
- Full Text
- View/download PDF
76. Efficacy and tolerability of treatments for chronic cough: a systematic review and meta-analysis.
- Author
-
Yancy WS Jr, McCrory DC, Coeytaux RR, Schmit KM, Kemper AR, Goode A, Hasselblad V, Heidenfelder BL, and Sanders GD
- Subjects
- Antitussive Agents classification, Chronic Disease, Humans, Outcome Assessment, Health Care, Severity of Illness Index, Treatment Outcome, Antitussive Agents adverse effects, Antitussive Agents therapeutic use, Cough drug therapy
- Abstract
Background: Understanding the comparative effectiveness of treatments for patients with unexplained or refractory cough is important to increase awareness of proven therapies and their potential adverse effects in this unique population., Methods: We performed a literature search for English-language studies published up to June 2012 that compared symptomatic therapies for chronic cough. Two investigators screened each abstract and full-text article for inclusion, abstracted data, and rated quality. Meta-analysis with random-effects models was used to summarize effects of treatments., Results: We identified 49 studies (3,067 patients) comprising 68 therapeutic comparisons. Of the studied agents, opioid and certain nonopioid and nonanesthetic antitussives had demonstrated efficacy for chronic cough in adults. Compared with placebo, effect sizes (standardized mean differences for cough severity and rate ratios for cough frequency) for opioids were 0.55 (95% CI, 0.38-0.72; P < .0001) and 0.57 (95% CI, 0.36-0.91; P = .0260), respectively. For dextromethorphan, effect sizes were 0.37 (95% CI, 0.19-0.56; P = .0008) and 0.40 (95% CI, 0.18-0.85; P = .0248), respectively. The overall strength of evidence was limited by inconsistency and imprecision of results and by small numbers of direct comparisons. Nonpharmacologic therapies and the management of cough in children were infrequently studied., Conclusions: Although evidence is limited, opioid and certain nonopioid and nonanesthetic antitussives demonstrated efficacy for treating chronic cough in adults. There is a need for further studies in patients with unexplained or refractory cough as well as for more systematic study designs, assessment of patient-centered outcomes, and reporting.
- Published
- 2013
- Full Text
- View/download PDF
77. Accuracy of clinicians and models for estimating the probability that a pulmonary nodule is malignant.
- Author
-
Balekian AA, Silvestri GA, Simkovich SM, Mestaz PJ, Sanders GD, Daniel J, Porcel J, and Gould MK
- Subjects
- Female, Humans, Male, Clinical Competence, Decision Support Techniques, Lung Neoplasms diagnosis, Physicians, Primary Care standards, Probability, Pulmonary Medicine standards, Solitary Pulmonary Nodule diagnosis
- Abstract
Rationale: Management of pulmonary nodules depends critically on the probability of malignancy. Models to estimate probability have been developed and validated, but most clinicians rely on judgment., Objectives: The aim of this study was to compare the accuracy of clinical judgment with that of two prediction models., Methods: Physician participants reviewed up to five clinical vignettes, selected at random from a larger pool of 35 vignettes, all based on actual patients with lung nodules of known final diagnosis. Vignettes included clinical information and a representative slice from computed tomography. Clinicians estimated the probability of malignancy for each vignette. To examine agreement with models, we calculated intraclass correlation coefficients (ICC) and kappa statistics. To examine accuracy, we compared areas under the receiver operator characteristic curve (AUC)., Measurements and Main Results: Thirty-six participants completed 179 vignettes, 47% of which described patients with malignant nodules. Agreement between participants and models was fair for the Mayo Clinic model (ICC, 0.37; 95% confidence interval [CI], 0.23-0.50) and moderate for the Veterans Affairs model (ICC, 0.46; 95% CI, 0.34-0.57). There was no difference in accuracy between participants (AUC, 0.70; 95% CI, 0.62-0.77) and the Mayo Clinic model (AUC, 0.71; 95% CI, 0.62-0.80; P = 0.90) or the Veterans Affairs model (AUC, 0.72; 95% CI, 0.64-0.80; P = 0.54)., Conclusions: In this vignette-based study, clinical judgment and models appeared to have similar accuracy for lung nodule characterization, but agreement between judgment and the models was modest, suggesting that qualitative and quantitative approaches may provide complementary information.
- Published
- 2013
- Full Text
- View/download PDF
78. Evaluating cough assessment tools: a systematic review.
- Author
-
Schmit KM, Coeytaux RR, Goode AP, McCrory DC, Yancy WS Jr, Kemper AR, Hasselblad V, Heidenfelder BL, and Sanders GD
- Subjects
- Adolescent, Adult, Child, Cough physiopathology, Cough psychology, Humans, Reproducibility of Results, Surveys and Questionnaires, Tape Recording, Visual Analog Scale, Young Adult, Cough diagnosis, Quality of Life psychology, Severity of Illness Index, Symptom Assessment methods
- Abstract
Background: Little is known about the comparative validity, reliability, or responsiveness of instruments for assessing cough frequency or impact, where the term impact encompasses both cough severity and the impact of cough on health-related quality of life., Methods: We conducted a systematic review to evaluate instruments that assess cough frequency or impact in adults, adolescents, and children with acute or chronic cough., Results: Seventy-eight studies were included, of which eight were randomized controlled trials and 70 were observational studies. In all age groups, audio and video electronic recording devices had good reliability compared with other methods of assessing cough frequency but had variable correlation with other cough assessments, such as visual analog scale scores, quality-of-life questionnaires, cough diaries, and tussigenic challenges. Among adult and adolescent patients, the Leicester Cough Questionnaire (LCQ) and the Cough-Specific Quality-of-Life Questionnaire (CQLQ) were valid and reliable, showing high intraclass and test-retest correlations. Among children, the Parent Cough-Specific Quality of Life Questionnaire and Pediatric Cough Questionnaire were valid and reliable., Conclusions: Electronic recording devices can be valid assessments of cough frequency. The LCQ and CQLQ for adults and the Parent Cough-Specific Quality of Life questionnaire for children are valid instruments for assessing cough impact. There is limited but insufficient evidence to determine the reliability or concurrent validity of the different types of cough diaries or visual analog scale scores. There are also limited data to support the responsiveness of recording devices. There is good responsiveness data for the LCQ and CQLQ, but more evidence is needed.
- Published
- 2013
- Full Text
- View/download PDF
79. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.
- Author
-
Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, and Myers ER
- Subjects
- BRCA1 Protein genetics, BRCA2 Protein genetics, Breast Neoplasms genetics, Female, Heterozygote, Humans, Mutation, Ovarian Neoplasms genetics, Risk Assessment, Breast Neoplasms chemically induced, Contraceptives, Oral adverse effects, Ovarian Neoplasms chemically induced
- Abstract
Purpose: To estimate the risks of ovarian cancer and breast cancer associated with oral contraceptive (OC) use among women at elevated risk owing to mutations in BRCA1/2 or a strong family history., Methods: We searched PubMed, Embase, the Cochrane Database of Systematic Reviews, and ClinicalTrials.gov for studies published 2000 to 2012 that evaluated associations between OC use and breast or ovarian cancer among women who are carriers of a BRCA1/2 mutation or have a family history of breast or ovarian cancer., Results: From 6,476 unique citations, we identified six studies examining ovarian cancer risk in BRCA1/2 mutation carriers and eight studies examining breast cancer risk in BRCA1/2 mutation carriers. For BRCA1/2 mutation carriers combined, meta-analysis showed an inverse association between OC use and ovarian cancer (odds ratio [OR], 0.58; 95% CI, 0.46 to 0.73) and a nonstatistically significant association with breast cancer (OR, 1.21; 95% CI, 0.93 to 1.58). Findings were similar when examining BRCA1 and BRCA2 mutation carriers separately. Data were inadequate to perform meta-analyses examining duration or timing of use. For women with a family history of ovarian or breast cancer, we identified four studies examining risk for ovarian cancer and three for breast cancer, but differences between studies precluded combining the data for meta-analyses, and no overall pattern could be discerned., Conclusion: Our analyses suggest that associations between ever use of OCs and ovarian and breast cancer among women who are BRCA1 or BRCA2 mutation carriers are similar to those reported for the general population.
- Published
- 2013
- Full Text
- View/download PDF
80. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review.
- Author
-
Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, and Myers ER
- Subjects
- Breast Neoplasms chemically induced, Contraceptives, Oral adverse effects, Endometrial Neoplasms chemically induced, Female, Humans, Ovarian Neoplasms chemically induced, Uterine Cervical Neoplasms chemically induced, Breast Neoplasms epidemiology, Contraceptives, Oral administration & dosage, Endometrial Neoplasms epidemiology, Ovarian Neoplasms epidemiology, Uterine Cervical Neoplasms epidemiology
- Abstract
Oral contraceptives may influence the risk of certain cancers. As part of the AHRQ Evidence Report, Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer, we conducted a systematic review to estimate associations between oral contraceptive use and breast, cervical, colorectal, and endometrial cancer incidence. We searched PubMed, Embase, and Cochrane Database of Systematic Reviews. Study inclusion criteria were women taking oral contraceptives for contraception or ovarian cancer prevention; includes comparison group with no oral contraceptive use; study reports quantitative associations between oral contraceptive exposure and relevant cancers; controlled study or pooled patient-level meta-analyses; sample size for nonrandomized studies ≥100; peer-reviewed, English-language; published from January 1, 2000 forward. Random-effects meta-analyses were conducted by estimating pooled ORs with 95% confidence intervals (CIs). We included 44 breast, 12 cervical, 11 colorectal, and 9 endometrial cancers studies. Breast cancer incidence was slightly but significantly increased in users (OR, 1.08; CI, 1.00-1.17); results show a higher risk associated with more recent use of oral contraceptives. Risk of cervical cancer was increased with duration of oral contraceptive use in women with human papillomavirus infection; heterogeneity prevented meta-analysis. Colorectal cancer (OR, 0.86; CI, 0.79-0.95) and endometrial cancer incidences (OR, 0.57; CI, 0.43-0.77) were significantly reduced by oral contraceptive use. Compared with never use, ever use of oral contraceptives is significantly associated with decreases in colorectal and endometrial cancers and increases in breast cancers. Although elevated breast cancer risk was small, relatively high incidence of breast cancers means that oral contraceptives may contribute to a substantial number of cases., (©2013 AACR.)
- Published
- 2013
- Full Text
- View/download PDF
81. Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation.
- Author
-
Allen LaPointe NM, Lokhnygina Y, Sanders GD, Peterson ED, and Al-Khatib SM
- Subjects
- Atrial Fibrillation complications, Cardiovascular Diseases drug therapy, Female, Humans, Male, Middle Aged, Treatment Outcome, Anti-Arrhythmia Agents therapeutic use, Atrial Fibrillation drug therapy, Cardiovascular Diseases complications, Guideline Adherence
- Abstract
Background: Atrial fibrillation (AF) guideline recommendations for antiarrhythmic drugs (AADs) are based on the effectiveness and safety of the AAD in patients with selected, concomitant heart disease. It is unknown to what extent these recommendations are being implemented in clinical practice., Methods: Using commercial health claims, patients with AF were identified and then categorized into mutually exclusive, guideline-established subgroups based on their most serious concurrent heart disease: heart failure, coronary artery disease (CAD), hypertension, and no heart disease. Antiarrhythmic drug use after the first AF encounter and the identified concurrent heart disease encounter was determined from prescription claims, and this was compared with guideline recommendations., Results: From January 2006 through December 2010, a total of 331,274 patients with AF aged < 65 years were identified: 18%, heart failure; 23%, CAD; 33%, hypertension; and 25%, no heart disease. Of these, 78,877 (24%) patients filled ≥ 1 qualifying AAD prescription. The median age was 57 years (interquartile range 52-61), and 69% were male. A total of 74,191 patients had AADs after both the AF and concurrent heart disease encounters: 27% with heart failure, 25% with CAD, 21% with hypertension, and 19% with no heart disease. In the heart failure and CAD subgroups, 45% and 31% of AADs were inconsistent with first- or second-line guideline recommendations, respectively., Conclusion: More than one-third of the AADs used in patients with AF and CAD or heart failure did not conform to guideline recommendations. This highlights the potential need for increased clinician education and intervention to improve the safe use of AADs for AF management., (© 2013.)
- Published
- 2013
- Full Text
- View/download PDF
82. When to implant an ICD following a myocardial infarction?
- Author
-
Hess PL, Al-Khatib SM, Inoue LY, and Sanders GD
- Subjects
- Female, Humans, Male, Death, Sudden, Cardiac prevention & control, Defibrillators, Implantable, Myocardial Infarction mortality, Myocardial Infarction therapy, Primary Prevention
- Published
- 2013
- Full Text
- View/download PDF
83. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis.
- Author
-
Peragallo Urrutia R, Coeytaux RR, McBroom AJ, Gierisch JM, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, Hasselblad V, Sanders GD, and Myers ER
- Subjects
- Female, Humans, Risk Assessment, Contraceptives, Oral, Hormonal adverse effects, Myocardial Infarction chemically induced, Stroke chemically induced, Venous Thromboembolism chemically induced
- Abstract
Objective: To estimate the risk of venous thromboembolism, stroke, or myocardial infarction (MI) associated with the use of oral contraceptive pills (OCPs) and to describe how these risks vary by dose or formulation., Data Sources: We searched PubMed, Embase, the Cochrane Database of Systematic Reviews, and ClinicalTrials.gov for studies published from January 1995 through June 2012 that evaluated the association between OCP use and risk of venous thromboembolism, stroke, or MI., Methods of Study Selection: We reviewed 6,476 citations. We included English-language, controlled studies with human participants reporting a quantitative association between exposure to OCPs and outcomes of venous thromboembolism, stroke, or MI. Two investigators independently reviewed articles for inclusion or exclusion; discordant decisions were resolved by team review and consensus. Random-effects meta-analysis was used to generate summary odds ratios (ORs)., Tabulation, Integration, and Results: Fifty studies met inclusion criteria. There were no randomized clinical trials. We found threefold increased odds of venous thromboembolism among current compared with noncurrent OCP users (14 studies; OR 2.97, 95% confidence interval [CI] 2.46-3.59). We found twofold increased odds of ischemic stroke (seven studies; OR 1.90, 95% CI 1.24-2.91). There was no evidence of increased risk of hemorrhagic stroke (four studies; OR 1.03, 95% CI 0.71-1.49) or MI (eight studies; OR 1.34, 95% CI 0.87-2.08)., Conclusion: Current use of combined OCPs is associated with increased odds of venous thromboembolism and ischemic stroke but not hemorrhagic stroke or MI.
- Published
- 2013
- Full Text
- View/download PDF
84. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis.
- Author
-
Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, and Myers ER
- Subjects
- Female, Humans, Ovarian Neoplasms epidemiology, Pregnancy, Risk, Risk Management, Contraceptives, Oral administration & dosage, Ovarian Neoplasms prevention & control, Primary Prevention methods
- Abstract
Objective: To estimate the overall reduction in ovarian cancer risk associated with the use of oral contraceptive pills (OCPs) and whether reduction in risk is affected by specifics of OCP use, such as formulation or duration of use., Data Sources: We searched PubMed, Embase, the Cochrane Database of Systematic Reviews, and ClinicalTrials.gov for studies published from January 1990 to June 2012, with primary analysis of studies published since January 2000., Methods of Study Selection: We reviewed 6,476 citations. We included English-language controlled studies with human participants reporting a quantitative association between exposure to OCPs (in which the explicit or implicit indication for OCP use was prevention of pregnancy or ovarian cancer) compared with no use of OCPs. Two investigators independently reviewed the title and abstract and full-text of articles for inclusion or exclusion decision; discordant decisions were resolved by team review and consensus., Tabulation, Integration, and Results: Fifty-five studies met inclusion criteria. A random-effects meta-analysis of 24 case-control and cohort studies showed significant reduction in ovarian cancer incidence in ever-users compared with never-users (odds ratio 0.73, 95% confidence interval 0.66-0.81). There was a significant duration-response relationship, with reduction in incidence of more than 50% among women using OCPs for 10 or more years. The lifetime reduction in ovarian cancer attributable to the use of OCPs is approximately 0.54% for a number-needed-to-treat of approximately 185 for a use period of 5 years., Conclusion: Significant duration-dependent reductions in ovarian cancer incidence in the general population are associated with OCP use.
- Published
- 2013
- Full Text
- View/download PDF
85. Oral contraceptive use for the primary prevention of ovarian cancer.
- Author
-
Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Urrutia RP, Lowery WJ, Dinan M, McBroom AJ, Wing L, Musty MD, Lallinger KR, Hasselblad V, Sanders GD, and Myers ER
- Subjects
- Female, Humans, Primary Prevention, Contraceptives, Oral administration & dosage, Ovarian Neoplasms prevention & control
- Abstract
Objective: To estimate the overall balance of harms and benefits from the potential use of oral contraceptives (OCs) for the primary prevention of ovarian cancer, Data Sources: We searched PubMed®, Embase®, the Cochrane Database of Systematic Reviews, and ClinicalTrials.gov for English-language studies published from January 1990 to June 2012 that evaluated the potential benefits (reduction in ovarian, colorectal, and endometrial cancers) and harms (increase in breast and cervical cancer, and vascular complications) of OC use., Review Methods: Two investigators screened each abstract and full-text article for inclusion; the investigators abstracted data, and they performed quality ratings, applicability ratings, and evidence grading. Random-effects models were used to compute summary estimates of effects. A simulation model was used to estimate the effects of OC use on the overall balance of benefits and harms., Results: We reviewed 55 studies relevant to ovarian cancer outcomes, 66 relevant to other cancers, and 50 relevant to vascular events. Ovarian cancer incidence was significantly reduced in OC users (OR [odds ratio], 0.73; 95% CI [confidence interval], 0.66 to 0.81), with greater reductions seen with longer duration of use. Breast cancer incidence was slightly but significantly increased in OC users (OR, 1.08; 95% CI, 1.00 to 1.17), with a significant reduction in risk as time since last use increased. The risk of cervical cancer was significantly increased in women with persistent human papillomavirus infection who used OCs, but heterogeneity prevented a formal meta-analysis. Incidences of both colorectal cancer (OR, 0.86; 95% CI, 0.79 to 0.95) and endometrial cancer (OR, 0.57; 95% CI, 0.43 to 0.76) were significantly reduced by OC use. The risk of vascular events was increased in current OC users compared with nonusers, although the increase in myocardial infarction was not statistically significant. The overall strength of evidence for ovarian cancer prevention was moderate to low, primarily because of the lack of randomized trials and inconsistent reporting of important characteristics of use, such as duration. The simulation model predicted that the combined increase in risk of breast and cervical cancers and vascular events was likely to be equivalent to or greater than the decreased risk in ovarian cancer, although the harm/benefit ratio was much more favorable when protection against endometrial and colorectal cancers was added, resulting in net gains in life expectancy of approximately 1 month., Conclusions: There is insufficient evidence to recommend for or against the use of OCs solely for the primary prevention of ovarian cancer. Although the net effects of the current patterns of OC use likely result in increased life expectancy when other noncontraceptive benefits are included, the harm/benefit ratio for ovarian cancer prevention alone is uncertain, particularly when the potential quality-of-life impact of breast cancer and vascular events are considered.
- Published
- 2013
86. Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials.
- Author
-
Hess PL, Laird A, Edwards R, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Hall WJ, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Al-Khatib SM, Piccini JP, Inoue LY, and Sanders GD
- Subjects
- Aged, Death, Sudden, Cardiac epidemiology, Female, Hospitalization statistics & numerical data, Humans, Male, Middle Aged, Myocardial Infarction complications, Proportional Hazards Models, Randomized Controlled Trials as Topic, Time Factors, Death, Sudden, Cardiac prevention & control, Defibrillators, Implantable adverse effects, Myocardial Infarction mortality, Myocardial Infarction therapy, Primary Prevention
- Abstract
Background: Whether there is an optimal time to place an implantable cardioverter-defibrillator (ICD) more than 40 days after myocardial infarction (MI) in guideline-eligible patients is unknown., Objective: To evaluate the effect of time from MI to randomization on mortality, rehospitalizations, and complications., Methods: Individual data on patients enrolled in 9 primary prevention ICD trials were provided. Clinical trials were eligible for the current analysis if they enrolled patients with an MI more than 40 days prior to randomization to primary prevention ICD therapy vs usual care: Multicenter Automatic Defibrillator Implantation Trial I, Multicenter UnSustained Tachyardia Trial, Multicenter Automatic Defibrillator Implantation Trial II, and Sudden Cardiac Death in Heart Failure Trial., Results: ICD recipients died less frequently than nonrecipients at 5 years across all subgroups of time from MI to randomization. In unadjusted Cox proportional hazards regression, a survival benefit was evident in most subgroups. Adjusted Bayesian Weibull survival modeling yielded hazard ratio (HR) 0.50, 95% posterior credible interval (PCI) 0.20-1.25 41-180 days after MI; HR 0.98, 95% PCI 0.37-2.37 181-365 days after MI; HR 0.22, 95% PCI 0.07-0.59>1-2 years after MI; HR 0.42, 95% PCI 0.17-0.90>2-5 years after MI; HR 0.55, 95% PCI 0.25-1.15>5-10 years after MI; and HR 0.48, 95% PCI 0.20-1.02>10 years after MI. There was no evidence of an interaction between time from MI and all-cause mortality, rehospitalizations, or complications., Conclusions: In this meta-analysis, there was scant evidence that the efficacy of primary prevention ICD therapy depends on time to implantation more than 40 days after MI. Similarly, there was no evidence that the risks of rehospitalizations or complications depend on time more than 40 days after MI., (Copyright © 2013 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
87. Performance measures to promote quality improvement in sudden cardiac arrest prevention and treatment.
- Author
-
Al-Khatib SM, Fonarow GC, Hayes DL, Curtis AB, Sears SF Jr, Sanders GD, Hernandez AF, Mirro MJ, Thomas KL, Eapen ZJ, Russo AM, and Yancy CW
- Subjects
- Humans, Incidence, Survival Rate, United States epidemiology, Cardiopulmonary Resuscitation standards, Death, Sudden, Cardiac epidemiology, Death, Sudden, Cardiac prevention & control, Emergency Medical Services standards, Public Health, Quality Improvement
- Abstract
Sudden cardiac arrest (SCA) is one of the most impactful public health problems in the United States. Despite the progress made in reducing the number of cardiac deaths, the incidence of sudden cardiac death remains high. Studies of life-saving interventions for prevention and treatment of SCA, like β-blockers, aldosterone antagonists, implantable cardioverter defibrillator therapy, automated external defibrillators, and cardiopulmonary resuscitation, have brought to light substantial underutilization, variations in care, and disparities. Thus, a comprehensive systems-based approach to addressing these gaps in care should be implemented. In addition to educating stakeholders about SCA and its prevention and developing tools that could help physicians identify patients who could benefit from primary prevention of SCA, robust performance measures with strong, evidence-based association between process performance and patient outcomes are needed. In this article, we review the burden of SCA and highlight the need to develop performance measures related to the prevention and treatment of SCA., (Copyright © 2013 Mosby, Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
88. Theory of coherent phonons in carbon nanotubes and graphene nanoribbons.
- Author
-
Sanders GD, Nugraha AR, Sato K, Kim JH, Kono J, Saito R, and Stanton CJ
- Abstract
We survey our recent theoretical studies on the generation and detection of coherent radial breathing mode (RBM) phonons in single-walled carbon nanotubes and coherent radial breathing like mode (RBLM) phonons in graphene nanoribbons. We present a microscopic theory for the electronic states, phonon modes, optical matrix elements and electron-phonon interaction matrix elements that allows us to calculate the coherent phonon spectrum. An extended tight-binding (ETB) model has been used for the electronic structure and a valence force field (VFF) model has been used for the phonon modes. The coherent phonon amplitudes satisfy a driven oscillator equation with the driving term depending on the photoexcited carrier density. We discuss the dependence of the coherent phonon spectrum on the nanotube chirality and type, and also on the graphene nanoribbon mod number and class (armchair versus zigzag). We compare these results with a simpler effective mass theory where reasonable agreement with the main features of the coherent phonon spectrum is found. In particular, the effective mass theory helps us to understand the initial phase of the coherent phonon oscillations for a given nanotube chirality and type. We compare these results to two different experiments for nanotubes: (i) micelle suspended tubes and (ii) aligned nanotube films. In the case of graphene nanoribbons, there are no experimental observations to date. We also discuss, based on the evaluation of the electron-phonon interaction matrix elements, the initial phase of the coherent phonon amplitude and its dependence on the chirality and type. Finally, we discuss previously unpublished results for coherent phonon amplitudes in zigzag nanoribbons obtained using an effective mass theory.
- Published
- 2013
- Full Text
- View/download PDF
89. Priorities for comparative effectiveness reviews in cardiovascular disease.
- Author
-
Eapen ZJ, McBroom AJ, Gray R, Musty MD, Hadley C, Hernandez AF, and Sanders GD
- Subjects
- Arrhythmias, Cardiac therapy, Cardiovascular Diseases diagnosis, Cardiovascular Diseases epidemiology, Cerebrovascular Disorders therapy, Chronic Disease, Consensus, Cooperative Behavior, Coronary Artery Disease therapy, Evidence-Based Medicine, Health Care Rationing, Health Priorities, Heart Failure therapy, Humans, Interdisciplinary Communication, Needs Assessment, Prevalence, Treatment Outcome, Cardiovascular Diseases therapy, Comparative Effectiveness Research, Outcome and Process Assessment, Health Care
- Abstract
Background: Comparative effectiveness reviews offer a systematic method to critically appraise existing research and to identify unaddressed clinical areas in cardiovascular disease where significant morbidity, mortality, and variation in the use of resources persist. To delineate and help select areas where comparative effectiveness reviews are needed, the Effective Health Care Program of the Agency for Healthcare Research and Quality involved stakeholders in prioritization of the research agenda., Methods and Results: We involved a diverse panel of stakeholders representing a broad range of clinical, policy, and patient perspectives. To assist in prioritization of topics for evidence synthesis, we created a framework evaluating 12 cardiovascular disease subcategories that reflect American College of Cardiology/American Heart Association disease-based guidelines. We performed an environmental scan for each disease subcategory to populate this framework with existing knowledge, levels of evidence, and degrees of public interest. Through a formalized process, 4 disease subcategories were prioritized: chronic coronary artery disease, ventricular arrhythmias, heart failure, and cerebrovascular disease. Within these subcategories, 11 topics that address the comparative safety and effectiveness of existing treatments and evaluate emerging treatments were nominated by the stakeholder panel to proceed for feasibility assessment before developing comparative effectiveness reviews., Conclusions: Using a systematic process deriving consensus from multiple stakeholders across cardiovascular disease states, we generated a prioritized list of evidence synthesis topics to inform decision makers. The topics vetted through this process seek to determine the comparative safety and effectiveness of a range of treatments, both established and emerging, and are immediately relevant for prevalent disease states.
- Published
- 2013
- Full Text
- View/download PDF
90. ECG-based signal analysis technologies for evaluating patients with acute coronary syndrome: a systematic review.
- Author
-
Leisy PJ, Coeytaux RR, Wagner GS, Chung EH, McBroom AJ, Green CL, Williams JW Jr, and Sanders GD
- Subjects
- Humans, Prevalence, Reproducibility of Results, Sensitivity and Specificity, Signal Processing, Computer-Assisted, Acute Coronary Syndrome diagnosis, Acute Coronary Syndrome epidemiology, Diagnosis, Computer-Assisted methods, Diagnosis, Computer-Assisted statistics & numerical data, Electrocardiography methods, Electrocardiography statistics & numerical data
- Abstract
Background/objectives: Timely identification of cardiac ischemia is critical in patients with acute coronary syndrome (ACS). The first test is often the standard, resting 12-lead ECG. Given its limitations, signal analysis enhancements have been proposed. We summarize the published evidence for commercially available ECG-based signal analysis technologies., Methods: This is a systematic review of the English-language published literature., Results: Published evidence meeting inclusion criteria was available for two devices: PRIME ECG and LP 3000. Meta-analysis of eight studies estimated a 68.4% sensitivity (95% CI, 35.1%-89.7%) and 91.4% specificity (CI, 83.6%-95.7%) for the PRIME ECG, compared with 40.5% sensitivity (CI, 19.6%-65.5%) and 95.0% specificity (CI, 87.9%-98.0%) for the standard 12-lead ECG., Conclusions: Existing evidence is insufficient to confidently inform the appropriate use of ECG-based signal analysis technologies for detecting ischemia or infarct in ACS. Further research is needed to determine in what circumstances, if any, these devices might precede, replace, or add to the standard ECG in test strategies for detecting ischemia or infarct in ACS., (Copyright © 2013 Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
91. Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications.
- Author
-
Atwater BD, Dai D, Allen-Lapointe NM, Al-Khatib SM, Zimmer LO, Sanders GD, and Peterson ED
- Subjects
- Adrenergic beta-Antagonists administration & dosage, Aged, Angiotensin-Converting Enzyme Inhibitors administration & dosage, Anticoagulants administration & dosage, Cardiac Resynchronization Therapy, Contraindications, Defibrillators, Implantable, Female, Heart Failure complications, Heart Failure diagnosis, Heart Failure drug therapy, Humans, Male, Middle Aged, Mineralocorticoid Receptor Antagonists administration & dosage, Severity of Illness Index, Cardiovascular Agents administration & dosage, Guideline Adherence statistics & numerical data, Heart Failure therapy
- Abstract
Background: Several studies based on claims data have reported underutilization of evidence-based heart failure (HF) therapies. The degree to which these estimates fail to account for therapeutic contraindications is unclear., Methods: We identified patients with HF and left ventricular ejection fraction ≤45% seen between January 1, 2010, and July 1, 2010, at a tertiary care Veterans Affairs Medical Center. Medical records were abstracted to evaluate utilization of and contraindications to β-blocker, angiotensin-converting enzyme inhibitor, aldosterone antagonist, anticoagulation for atrial fibrillation, implantable cardioverter-defibrillator, and cardiac resynchronization therapies., Results: Of the 178 patients with HF and an ejection fraction ≤45%, 78 (44%) received every guideline-recommended therapy. After accounting for medical contraindications, 77 (72%) of 107 patients received every guideline-recommended therapy. Adherence to recommendations for β-blocker (98%), angiotensin-converting enzyme inhibitor/angiotensin blocker (95%), and anticoagulation (97%) were better than adherence to implantable cardioverter-defibrillator (82%), cardiac resynchronization therapy (59%), or aldosterone antagonist (51%) recommendations. In adjusted analysis, lower New York Heart Association functional class and care by a cardiologist were associated with improved guideline adherence (P < .001)., Conclusions: Many patients with HF have therapeutic contraindications, and a failure to account for these may lead to a large underestimation of the true guideline adherence rates., (Copyright © 2012 Mosby, Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
92. Identifying research needs for improving health care.
- Author
-
Chang SM, Carey TS, Kato EU, Guise JM, and Sanders GD
- Subjects
- Evidence-Based Medicine economics, Evidence-Based Medicine trends, Health Priorities economics, Health Services Research economics, Humans, Research Design, Research Support as Topic, Health Priorities trends, Health Services Research trends
- Abstract
Insights from systematic reviews can help new studies better meet the priorities and needs of patients and communities. However, systematic reviews unfortunately have not yet achieved this position to direct and guide new research studies. The Agency for Healthcare Research and Quality's Evidence-based Practice Center Program uses systematic reviews to identify gaps in current evidence and has developed a systematic process of prioritizing these gaps with stakeholder input into clearly defined "future research needs." Eight Evidence-based Practice Centers began to apply this effort in 2010 to various clinical and policy topics. Gaps that prevented systematic reviewers from answering central questions of the review may include insufficient studies on subpopulations, insufficient studies with appropriate comparators, lack of appropriate outcomes measured, and methods problems. Stakeholder panels, consisting of advocacy groups, patients, researchers, clinicians, funders, and policymakers, help refine the gaps through multiple conference calls and prioritization exercises. Each report highlights a focused set of 4 to 15 high-priority needs with an accompanying description of possible considerations for study design. Identification of high-priority research needs could potentially speed the development and implementation of high-priority, stakeholder-engaged research.
- Published
- 2012
- Full Text
- View/download PDF
93. Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information.
- Author
-
Powers BJ, Coeytaux RR, Dolor RJ, Hasselblad V, Patel UD, Yancy WS Jr, Gray RN, Irvine RJ, Kendrick AS, and Sanders GD
- Subjects
- Angiotensin Receptor Antagonists adverse effects, Angiotensin Receptor Antagonists therapeutic use, Angiotensin-Converting Enzyme Inhibitors adverse effects, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Antihypertensive Agents adverse effects, Cardiovascular Diseases prevention & control, Evidence-Based Medicine, Female, Humans, Medication Adherence, Middle Aged, Protease Inhibitors adverse effects, Protease Inhibitors therapeutic use, Renin antagonists & inhibitors, Antihypertensive Agents therapeutic use, Hypertension drug therapy
- Abstract
Objectives: A 2007 systematic review compared angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) in patients with hypertension. Direct renin inhibitors (DRIs) have since been introduced, and significant new research has been published. We sought to update and expand the 2007 review., Data Sources: We searched MEDLINE and EMBASE (through December 2010) and selected other sources for relevant English-language trials., Study Eligibility Criteria, Participants, and Interventions: We included studies that directly compared ACE inhibitors, ARBs, and/or DRIs in at least 20 total adults with essential hypertension; had at least 12 weeks of follow-up; and reported at least one outcome of interest. Ninety-seven (97) studies (36 new since 2007) directly comparing ACE inhibitors versus ARBs and three studies directly comparing DRIs to ACE inhibitor inhibitors or ARBs were included., Study Appraisal and Synthesis Methods: A standard protocol was used to extract data on study design, interventions, population characteristics, and outcomes; evaluate study quality; and summarize the evidence., Results: In spite of substantial new evidence, none of the conclusions from the 2007 review changed. The level of evidence remains high for equivalence between ACE inhibitors and ARBs for blood pressure lowering and use as single antihypertensive agents, as well as for superiority of ARBs for short-term adverse events (primarily cough). However, the new evidence was insufficient on long-term cardiovascular outcomes, quality of life, progression of renal disease, medication adherence or persistence, rates of angioedema, and differences in key patient subgroups., Limitations: Included studies were limited by follow-up duration, protocol heterogeneity, and infrequent reporting on patient subgroups., Conclusions and Implications of Key Findings: Evidence does not support a meaningful difference between ACE inhibitors and ARBs for any outcome except medication side effects. Few, if any, of the questions that were not answered in the 2007 report have been addressed by the 36 new studies. Future research in this area should consider areas of uncertainty and be prioritized accordingly.
- Published
- 2012
- Full Text
- View/download PDF
94. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: Future research needs prioritization.
- Author
-
Crowley MJ, Powers BJ, Myers ER, McBroom AJ, and Sanders GD
- Subjects
- Dose-Response Relationship, Drug, Drug Administration Schedule, Evidence-Based Medicine, Female, Focus Groups, Follow-Up Studies, Forecasting, Health Services Research, Humans, Male, Myocardial Ischemia diagnosis, Myocardial Ischemia mortality, Needs Assessment, Randomized Controlled Trials as Topic, Research Design, Risk Assessment, Severity of Illness Index, Treatment Outcome, United States, Angiotensin II Type 1 Receptor Blockers therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Myocardial Ischemia drug therapy, Research organization & administration
- Abstract
Background: A recent review evaluated the comparative effectiveness of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) in patients with or at high risk for stable ischemic heart disease (IHD). The prioritization of future research needs has customarily been an informal process that is not responsive to the needs of all relevant stakeholders., Methods: As part of the Agency for Healthcare Research and Quality Effective Healthcare Program, the Duke Evidence-Based Practice Center engaged a diverse stakeholder group in 3 exercises designed to prioritize future research needs pertaining to the comparative effectiveness of ACE-I/ARB in patients with stable IHD., Results: Our stakeholders prioritized the following areas of research pertaining to the comparative effectiveness of ACE-I/ARB in stable IHD: (1) strategies to enhance greater evidence-based use, (2) impact of adherence on effectiveness or harms, (3) impact of comorbidities on effectiveness or harms, (4) medication impact on patient quality of life, (5) impact of demographic differences on effectiveness or harms, and (6) medication impact on incidence of new diagnoses. This project also yielded suggestions regarding potential study designs to address these future research needs., Conclusions: Our stakeholders prioritized research designed to facilitate (1) tailored ACE-I/ARB treatment based on individual patient characteristics and (2) implementation of ACE-I/ARB use among patients most likely to benefit. With respect to suggested study designs, it was felt that analysis of existing data would sufficiently address many of the top-tier future research needs (FRNs)., (Copyright © 2012 Mosby, Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
95. Enabling health care decisionmaking through clinical decision support and knowledge management.
- Author
-
Lobach D, Sanders GD, Bright TJ, Wong A, Dhurjati R, Bristow E, Bastian L, Coeytaux R, Samsa G, Hasselblad V, Williams JW, Wing L, Musty M, and Kendrick AS
- Subjects
- Decision Making, Female, Humans, Male, Preventive Health Services organization & administration, Randomized Controlled Trials as Topic, Treatment Outcome, Decision Support Systems, Clinical organization & administration, Delivery of Health Care organization & administration, Knowledge Management
- Abstract
Objectives: To catalogue study designs used to assess the clinical effectiveness of CDSSs and KMSs, to identify features that impact the success of CDSSs/KMSs, to document the impact of CDSSs/KMSs on outcomes, and to identify knowledge types that can be integrated into CDSSs/KMSs., Data Sources: MEDLINE(®), CINAHL(®), PsycINFO(®), and Web of Science(®)., Review Methods: We included studies published in English from January 1976 through December 2010. After screening titles and abstracts, full-text versions of articles were reviewed by two independent reviewers. Included articles were abstracted to evidence tables by two reviewers. Meta-analyses were performed for seven domains in which sufficient studies with common outcomes were included., Results: We identified 15,176 articles, from which 323 articles describing 311 unique studies including 160 reports on 148 randomized control trials (RCTs) were selected for inclusion. RCTs comprised 47.5 percent of the comparative studies on CDSSs/KMSs. Both commercially and locally developed CDSSs effectively improved health care process measures related to performing preventive services (n = 25; OR 1.42, 95% confidence interval [CI] 1.27 to 1.58), ordering clinical studies (n = 20; OR 1.72, 95% CI 1.47 to 2.00), and prescribing therapies (n = 46; OR 1.57, 95% CI 1.35 to 1.82). Fourteen CDSS/KMS features were assessed for correlation with success of CDSSs/KMSs across all endpoints. Meta-analyses identified six new success features: Integration with charting or order entry system. Promotion of action rather than inaction. No need for additional clinician data entry. Justification of decision support via research evidence. Local user involvement. Provision of decision support results to patients as well as providers. Three previously identified success features were confirmed: Automatic provision of decision support as part of clinician workflow. Provision of decision support at time and location of decisionmaking. Provision of a recommendation, not just an assessment. Only 29 (19.6%) RCTs assessed the impact of CDSSs on clinical outcomes, 22 (14.9%) assessed costs, and 3 assessed KMSs on any outcomes. The primary source of knowledge used in CDSSs was derived from structured care protocols., Conclusions: Strong evidence shows that CDSSs/KMSs are effective in improving health care process measures across diverse settings using both commercially and locally developed systems. Evidence for the effectiveness of CDSSs on clinical outcomes and costs and KMSs on any outcomes is minimal. Nine features of CDSSs/KMSs that correlate with a successful impact of clinical decision support have been newly identified or confirmed.
- Published
- 2012
96. Psychometric characteristics of outcome measures in juvenile idiopathic arthritis: a systematic review.
- Author
-
van Mater HA, Williams JW Jr, Coeytaux RR, Sanders GD, and Kemper AR
- Subjects
- Adolescent, Child, Child, Preschool, Disability Evaluation, Humans, Psychometrics, Quality of Life psychology, Surveys and Questionnaires, Arthritis, Juvenile psychology, Arthritis, Juvenile therapy, Outcome Assessment, Health Care
- Abstract
Objective: To review the performance characteristics of the instruments most commonly used to measure clinical outcomes in juvenile idiopathic arthritis (JIA), including global assessments, articular indices, functional/disability assessments, and quality of life measures., Methods: As part of an Agency for Healthcare Research and Quality comparative effectiveness review of antirheumatic drugs, we explored the characteristics of commonly used outcome measures for JIA. English-language studies of children with JIA were identified from Medline and Embase. Two independent reviewers screened titles and abstracts, with subsequent full-text review of studies selected based on predetermined criteria., Results: We included 35 publications describing 34 unique studies and involving 14,831 patients. The Childhood Health Assessment Questionnaire (C-HAQ) was the most extensively studied instrument and had high reliability, but only moderate correlations with other indices of disease activity and poor responsiveness to change in disease status. The physician global assessment of disease activity (PGA) and articular indices had the strongest association with disease activity and were the most responsive to change. Measures of psychosocial function and quality of life were moderately associated with measures of disease activity, but were less responsive to changes in disease status., Conclusion: In children with JIA, no single instrument was superior in reliability or validity or in describing the impact of JIA. Although the C-HAQ has been extensively evaluated, the PGA and articular indices appear to have the highest responsiveness to change and, therefore, the highest potential for detecting important differences in treatment response., (Copyright © 2012 by the American College of Rheumatology.)
- Published
- 2012
- Full Text
- View/download PDF
97. A pilot study using an implantable device to characterize cardiac arrhythmias in hemodialysis patients: implications for future research.
- Author
-
Pun PH, Schumm D, Sanders GD, Hickey D, Middleton JP, Clapp-Channing N, and Al-Khatib SM
- Subjects
- Humans, Pilot Projects, Prospective Studies, Arrhythmias, Cardiac diagnosis, Arrhythmias, Cardiac physiopathology, Death, Sudden, Cardiac, Electrocardiography, Ambulatory instrumentation, Renal Dialysis
- Published
- 2012
- Full Text
- View/download PDF
98. Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis.
- Author
-
Kemper AR, Van Mater HA, Coeytaux RR, Williams JW Jr, and Sanders GD
- Subjects
- Antirheumatic Agents adverse effects, Child, Child, Preschool, Comparative Effectiveness Research, Humans, Methotrexate adverse effects, Treatment Outcome, United States, United States Agency for Healthcare Research and Quality, Antirheumatic Agents therapeutic use, Arthritis, Juvenile drug therapy, Methotrexate therapeutic use
- Abstract
Background: Treatment of juvenile idiopathic arthritis (JIA) with disease-modifying antirheumatic drugs (DMARDs) may improve outcomes compared to conventional therapy (e.g., non-steroidal anti-inflammatory drugs, intra-articular corticosteroids). The purpose of this systematic review was to evaluate the comparative effectiveness and safety of DMARDs versus conventional therapy and versus other DMARDs., Results: A systematic evidence review of 156 reports identified in MEDLINE®, EMBASE®, and by hand searches. There is some evidence that methotrexate is superior to conventional therapy. Among children who have responded to a biologic DMARD, randomized discontinuation trials suggest that continued treatment decreases the risk of having a flare. However, these studies evaluated DMARDs with different mechanisms of action (abatacept, adalimumab, anakinra, etanercept, intravenous immunoglobulin, tocilizumab) and used varying comparators and follow-up periods. Rates of serious adverse events are similar between DMARDs and placebo in published trials. This review identified 11 incident cases of cancer among several thousand children treated with one or more DMARD., Conclusions: Few data are available to evaluate the comparative effectiveness of either specific DMARDs or general classes of DMARDs. However, based on the overall number, quality, and consistency of studies, there is moderate strength of evidence to support that DMARDs improve JIA-associated symptoms. Limited data suggest that short-term risk of cancer is low.
- Published
- 2012
- Full Text
- View/download PDF
99. Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis.
- Author
-
Holland DP, Sanders GD, Hamilton CD, and Stout JE
- Subjects
- Animals, Aza Compounds therapeutic use, Cost-Benefit Analysis, Drug Therapy economics, Drug Therapy methods, Drug Therapy, Combination, Ethambutol therapeutic use, Fluoroquinolones, Humans, Isoniazid therapeutic use, Mice, Models, Theoretical, Moxifloxacin, Outcome Assessment, Health Care, Quality-Adjusted Life Years, Quinolines therapeutic use, Rifampin therapeutic use, Antitubercular Agents therapeutic use, Decision Support Techniques, Markov Chains, Tuberculosis, Multidrug-Resistant drug therapy
- Abstract
Background: The optimal treatment for latent multiple-drug resistant tuberculosis infection remains unclear. In anticipation of future clinical trials, we modeled the expected performance of six potential regimens for treatment of latent multiple-drug resistant tuberculosis., Methods: A computerized Markov model to analyze the total cost of treatment for six different regimens: Pyrazinamide/ethambutol, moxifloxacin monotherapy, moxifloxacin/pyrazinamide, moxifloxacin/ethambutol, moxifloxacin/ethionamide, and moxifloxacin/PA-824. Efficacy estimates were extrapolated from mouse models and examined over a wide range of assumptions., Results: In the base-case, moxifloxacin monotherapy was the lowest cost strategy, but moxifloxacin/ethambutol was cost-effective at an incremental cost-effectiveness ratio of $21,252 per quality-adjusted life-year. Both pyrazinamide-containing regimens were dominated due to their toxicity. A hypothetical regimen of low toxicity and even modest efficacy was cost-effective compared to "no treatment.", Conclusion: In our model, moxifloxacin/ethambutol was the preferred treatment strategy under a wide range of assumptions; pyrazinamide-containing regimens fared poorly because of high rates of toxicity. Although more data are needed on efficacy of treatments for latent MDR-TB infection, data on toxicity and treatment discontinuation, which are easier to obtain, could have a substantial impact on public health practice.
- Published
- 2012
- Full Text
- View/download PDF
100. Quality of care for sudden cardiac arrest: Proposed steps to improve the translation of evidence into practice.
- Author
-
Eapen ZJ, Peterson ED, Fonarow GC, Sanders GD, Yancy CW, Sears SF Jr, Carlson MD, Curtis AB, Hall LL, Hayes DL, Hernandez AF, Mirro M, Prystowsky E, Russo AM, Thomas KL, and Al-Khatib SM
- Subjects
- Death, Sudden, Cardiac epidemiology, Decision Support Techniques, Humans, Program Evaluation, Survival Rate trends, United States epidemiology, Death, Sudden, Cardiac prevention & control, Healthcare Disparities, Policy Making, Quality Assurance, Health Care
- Abstract
Sudden cardiac arrest (SCA) is the most common cause of death in the United States. Despite national guidelines, patients at risk for SCA often fail to receive evidence-based therapies. Racial and ethnic minorities and women are at particularly high risk for undertreatment. To address the persistent challenges in improving the quality of care for SCA, the Duke Center for the Prevention of Sudden Cardiac Death at the Duke Clinical Research Institute (Durham, NC) reconvened the Sudden Cardiac Arrest Thought Leadership Alliance. Experts from clinical cardiology, cardiac electrophysiology, health policy and economics, the US Food and Drug Administration, the Centers for Medicare and Medicaid Services, the Agency for Health Care Research and Quality, and device and pharmaceutical manufacturers discussed the development of SCA educational tools for patients and providers, mechanisms of implementing successful tools to help providers identify patients in their practice at risk for SCA, disparities in SCA prevention, and performance measures related to SCA care. This article summarizes the discussions held at this meeting., (Copyright © 2011 Mosby, Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.